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BACKGROUND. Raf kinase inhibitor protein (RKIP) has been shown to act as a metastasis
suppressor gene in multiple models of cancer. Loss of RKIP expression promotes invasion and
metastasis in cell transplantation animal models. However, it is unknown if RKIP expression
can impact the progression of cancer in an autochthonous model of cancer. The goal of this
study was to determine if loss of RKIP expression in a genetic mouse model of prostate cancer
(PCa) impacts metastasis.
METHODS. Endogenous RKIP expression was measured in the primary tumors and
metastases of transgenic adenocarcinoma of the mouse prostate (TRAMPþ) mice. RKIP
knockout mice (RKIP/) were crossbred with (TRAMPþ) mice to create RKIP/TRAMPþ
mice. Mice were euthanized at 10, 20, and 30 weeks for evaluation of primary and metastatic
tumor development. To determine if loss of RKIP alone promotes metastasis, RKIP was
knocked down in the low metastatic LNCaP prostate cancer cell line.
RESULTS. Endogenous RKIP expression decreased in TRAMPþ mice as tumors progressed.
Primary tumors developed earlier in RKIP/TRAMPþ compared to TRAMPþ mice. At
30 weeks of age, distant metastases were identified only the RKIP/TRAMPþ mice. While
prostate epithelial cell proliferation rates were higher at 10 and 20 weeks in RKIP/TRAMPþ
compared to TRAMPþ mice, by 30 weeks there was no difference. Apoptosis rates in both
groups were similar at all timepoints. Decreased RKIP expression did not impact the
metastatic rate of LNCaP in an orthotopic PCa model.
CONCLUSIONS. These results demonstrate that loss of RKIP decreases latency of tumor
development and promotes distant metastasis in the TRAMP mouse model in the context of a
pro-metastatic background; but loss of RKIP alone is insufficient to promote metastasis. These
findings suggest that in addition to its known metastasis suppressor activity, RKIP may
promote tumor progression through enhancing tumor initiation. Prostate 75:292–302, 2015.
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INTRODUCTION
Raf kinase inhibitor protein (RKIP), originally identi-
fied as a phosphatidylethanolamine-binding protein
(PEBP), was demonstrated to inhibit Raf-1-mediated
phosphorylation of MEK-1 through competitively
binding to these signaling proteins [1]. The resulting
inhibition of MEK-1 activation culminates in inhibition
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of MEK-1-mediated activation of extracellular signal-
regulated kinase (ERK) activation. Additional studies
have shown that RKIP regulates multiple critical
signaling pathways including inhibition of Stat3 [2,3]
and NFkB [4]. Due to impact on so many signaling
pathways, RKIP modulates many important cellular
functions including spermatogenesis, immune response,
and neuropeptide production (reviewed in Ref. [5,6])
and may contribute to pathological states such as
Alzheimer’s disease [7] and cancer [8].
Initial studies regarding RKIP’s role in cancer
demonstrated that it modulates apoptosis in response
to chemotherapeutics in cancer cells [9–11] and serves
as a metastasis suppressor gene in prostate cancer
(PCa) [12]. Since these initial findings, decreased RKIP
expression has been shown to play a role in multiple
cancers based on clinical tissue and experimental data
(reviewed in Ref. [8]). In the majority of experimental
studies to determine RKIP function in cancer, RKIP
expression has either been knocked down or over-
expressed in cancer cell lines. While these studies have
highlighted the importance of RKIP, they are limited
by the use of established cancer cell lines in which the
transformation to cancer has already occurred. This
makes it challenging to determine the impact of RKIP
loss prior to normal cells transforming to cancer cells.
Understanding the role of RKIP in transformation
and tumor progression can lead towards identifying
important cellular pathways for identifying putative
therapeutic targets. Accordingly, the goal of this study
was to determine if RKIP deficiency prior to the onset
of cancer promotes PCa progression.
MATERIALSANDMETHODS
Animals and PCRGenotyping
Parental RKIP knockout mice created in a C57Bl/6
background were previously described [13]. C57Bl/6
heterozygous TRAMP females were purchased from
Jackson Labs (Bar Harbor, ME). RKIP knockout males
were bred with TRAMPþ females. RKIPþ/þTRAMPþ,
RKIP/TRAMPþ, and RKIP/TRAMPwere gener-
ated through successive backcross and sibling breed-
ing. Normal mice (genotyped to ensure they did not
contain the genetic mutations) were derived from the
knockout breeding colony. Mouse handling and breed-
ing were performed following the guidelines set by
UCUCA of the University of Michigan. PCR genotyp-
ing was performed with GoTaq DNA Polymerase
(Promega Corp, Madison, WI) using 50ng of DNA
template and the RKIP primers: RKIP WT FOR—
gagccctggccggtctcccttgtcccaaacttt (final 0.2mM), RKIP
WT REV gacttccgtgtccggatgatagatagcctctcc (0.1mM)
and RKIP KO REV (BGEOR2) ccaaaagggtctttgagcacca-
gaggacatccg (0.1mM) [5]. T-antigen primers were
designed to multiplex PCR with b-globin as internal
housekeeping gene marker: Probasin SV40 Large
TAg FOR—ccggtcgaccggaagcttccacaagtgcattta; TAg
REV—aggcattccaccactgctcccattcatc b-globin 2589FOR—
gccaatctgctcacacaggata; b-globin 3128REV—catg-
cagcttgtcacagtgga. RKIP and TAg-globin PCR was
performed at 60°C annealing temperature. All primers
were synthesized by InVitrogen (Life Technologies, Inc.,
Carlsbad, CA).
RT-PCR, qPCR
Tissues were homogenized in Trizol reagent (Life
Technologies, Inc.) with a Qiagen TissueLyzer and
total RNA was extracted using RNeasy Mini Kit
(Qiagen, Hilden, Germany). cDNA synthesis was
performed using random hexamers or oligo-dT and
MuLV RT (Promega) or using miScript cDNA synthe-
sis kit (Qiagen). One out of ten dilution of the cDNAs
were used for non-quantitative PCR. For RKIP RT-
PCR, the following primers were used: RKIP exon 1
FOR primer—gagctgggcaaagtgctaac, RKIP exon 2 REV
primer—gtctgtgaggaccagggtgt. SV40 large T-antigen
mRNAs were amplified using TAg qPCR primers, TAg
FOR—gtcagtgaggtccagatacctacc, TAg REV—cagg-
cactcctttcaagaccta. LightCycler Probe Master was used
for qPCR reaction using 1/50 dilution of the cDNA.
Probe #3 (0.1mM) of the Universal Probe Library
(Roche Applied Sciences, Basel, Switzerland) was
used for RKIP with the following designed primers:
mouse RKIP probe left primer tcctcacagaccccgatg,
mouse RKIP probe right primer, agtggtgccactccctga.
Probe #63 of the UPL was used for mouse b-actin with
the UPL-recommended primers. For T-antigen amplifi-
cation, Light Cycler SYBR Green Master was used
with the T-antigen qPCR primers above. Mouse 18S
rRNA was used as reference gene. qPCR was per-
formed in a Roche LC480 machine using Roche Light
Cycler 480 Probes Master reagent in 384 well plates.
All reactions were performed in triplicate and repeated
three times.
Antibodies forWestern and IHC
Thirty micrograms of protein were loaded into 10%
gel for protein transfer and antibody development.
RKIP was visualized using Rabbit anti-RKIP (N-term)
from InVitrogen (Life Technologies, Inc.) or mouse
anti-RKIP MAb from Zymed Laboratories (San
Francisco, CA). The SCBT (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA) antibody H17 Goat polyclonal
anti-RKIP was used for RKIP IHC. T-antigen antibody
PAb 101 from BD Pharmingen (BD BioSciences, San
Jose, CA) or rabbit anti-SV40 T Ag antibody V-300
from SCBTwere utilized for western and IHC. Western
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development was performed using the SuperSignal
West Dura Extended Duration Substrate or the Super-
Signal West Pico Chemiluminescent Substrate (Thermo
Fisher Scientific, Waltham, MA). Bands were measured
using densitometry.
Longitudinal Study
All animal studies were approved by the University
of Michigan Animal Use and Care Committee. Double
hybrid males RKIPþ/þTRAMPþ (n¼ 38), RKIP/
TRAMP (n¼ 34) and RKIP/TRAMPþ (n¼ 43)
were randomly assigned into cohorts for sacrifice at 10,
20, or 30 weeks. Total mice numbers were based on the
available male mice at the initiation of the study for
each genotype and power analysis. At a minimum of
10 mice per group per time point there was >90%
power to detect a difference of 60% between groups at
P< 0.05. At sacrifice, the dorsolateral and ventral lobes
of the prostate or the prostate tumor were dissected
along with the seminal vesicle, major organs (lungs,
liver, heart, kidney, brain, and spleen) and measurable
lymph nodes. Tissues were weighed, prostate tumors
were measured, and macroscopic lesions (suspected
tumor metastasis sites) were recorded. Tissues were
fixed in 10% (v/v) phosphate-buffered formalin for 24–
48hr at 4°C then transferred to cold 70% ethanol.
Paraffin imbedded tissues were sectioned at 5mm thick
and mounted on Plus slides. Sections were stained
with H&E, RKIP antibody or T-antigen antibody.
Orthotopic Tumor Studies
LNCaP cells or C4-2B cells [14] (105 cells) with
various modulations of RKIP were injected into
dorsolateral lobe of prostates of SCID mice (n¼ 10/
group) and allowed to form tumors for 12 weeks at
which time mice were euthanized. At necropsy, PCa
tumors and lungs were removed, fixed in 10% normal
buffered formalin, and transferred to 70% EtOH. After
24 hr, the samples were paraffin embedded. Each
sample was sectioned four times at 300mm intervals
and stained with hematoxylin and eosin and prostate
specific antigen (PSA).
BoydenChamberAssays
LNCaP cells (2.5 104) were plated in triplicate in
Boyden Chamber wells and control wells containing
just membrane (BD Biosciences, Franklin Lakes, NJ).
Medium with 5% FBS was placed in the upper
chamber with the cells and medium with 10% FBS was
placed in the lower chamber. Plates were incubated for
24 hr at 37°C. Cells were detected by HEMA 3 stain
(Catalog # 122–911, Fisher Scientific, Kalamazoo, MI)
and quantified using microscopic detection. Invasive
ability was defined as proportion of cells penetrating
coated wells divided by number of cells migrating
through uncoated membranes. Assays were per-
formed in triplicate and repeated at least twice.
Statistical Analysis
One-way ANOVA analysis was used to determine
statistical significance with or without a post hoc test
for most results. Proportion of Ki-67 was analyzed
using a linear mixed model with repeated measures to
account for the many areas examined within each
mouse. Pairwise comparisons between genotypes were
tested for each necropsy time within the model. Surviv-
al time for each necropsy group was analyzed using
product limit estimates from the Kaplan–Meier method.
The log-rank test was used with Tukey–Kramer adjust-
ments for multiple pairwise comparisons of survival
times between genotypes. GraphPad PRISM and SAS
9.2 (SAS Institute, Cary, NC) were used for analysis.
RESULTS
RKIPExpressionDeclines inTRAMPMiceDuring
Progressionof Prostatic Disease From
PIN toMetastasis
Loss of RKIP expression is associated with increased
metastasis [8]. In clinical PCa tissue, RKIP expression
decrease in primary tumors compared to non-cancer
prostate and further decreased in metastases compared
to primary tumors [15]. These results suggest that as
PCa progresses, RKIP expression declines; however, as
these tissues are taken from different patients and at
different time points; it is possible that this association
is not reflective of the pathogenesis of PCa. To explore
if RKIP declines as PCa progresses, we evaluated the
expression of RKIP in the prostates of the transgenic
adenocarcinoma of the mouse prostate (TRAMP)
mouse model of PCa. Use of a well-defined model
of PCa enables evaluation of RKIP expression with
consistency between tumors. RKIP expression declined
as PCa progressed with RKIP expression in primary
tumors lower than that in normal prostate and RKIP
expression in metastases was lower than that that of
primary tumors (Fig. 1a). The decline of RKIP expres-
sion was found in multiple metastatic sites including
lymph node, lung, and liver (Fig. 1b).
Generationof RKIPDef|cient
TRAMPMice
The finding that RKIP expression declined as PCa
tumors progressed in TRAMP mice is consistent with
the concept that loss of RKIP is a driver of tumor
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progression. However, it is also possible that loss of
RKIP expression is just a passenger and has no impact
on PCa progression. To delineate if RKIP has a role in
PCa progression, mice with the rkip gene knocked out
(RKIP/) [13] were bred with TRAMP mice to
generate TRAMP mice deficient in RKIP expression
(RKIP/TRAMPþ). The genotypes of mice were
confirmed using DNA PCR genotyping of tail clips
(not shown). To further ensure that prostate RKIP and
TAg expression reflected the genotypes, we evaluated
prostate RKIP and TAg mRNA and protein expression.
RKIP mRNA and protein expression were absent;
whereas, TAg mRNA and protein expression was
present in lysates and intact tissues of the prostates of
RKIP/TRAMPþ mice (Fig. 2). The overexpression of
TAg in the prostate accounts for the occurrence of PCa
in the TRAMP mice. Thus, it is plausible that modula-
tion of TAg expression could impact PCa development
or progression. To ensure any phenotypes we ob-
served were not due to RKIP-mediated modulation of
TAg, we measured TAg mRNA expression in the
different prostate lobes of the mice. No difference in
TAg expression was observed among the different
groups of mice and, as expected, the TAg expression
was localized to the prostate (Fig. 2d). Taken together,
these findings indicate that RKIP/TRAMPþ mice
have been successfully created and that phenotypes
mediated by loss of RKIP expression are not due to
changes in TAg expression.
Loss of RKIPPromotes Primary PCaGrowth in
TRAMPMice
In order to determine the impact of loss of RKIP
expression on PCa progression, we established colo-
nies of RKIP/TRAMPþ, RKIP/TRAMP, and
RKIPþ/þTRAMPþ, and euthanized mice at 10, 20, or
30 weeks old to evaluate PCa progression. There was
no significant difference in the average weights of the
major organs at all timepoints (not shown). In contrast,
while there were no tumors in the RKIP/TRAMP
mice, tumors developed in both the RKIPþ/þTRAMPþ
and the RKIP/TRAMPþ mice with tumors in the
latter group being larger at 30 weeks (Fig. 3a). The
incidence of primary prostate tumor is summarized in
Table I and pathology is depicted in Figure 3b. At
20 weeks, almost 60% of RKIP/TRAMPþ mice had
PCa; whereas, none of the RKIPþ/þTRAMPþ had
measurable PCa. At 30 weeks, approximately 90% of
the RKIP/TRAMPþ mice had PCa; whereas, ap-
proximately 33% of the RKIPþ/þTRAMPþ mice had
measureable PCa. The remaining RKIPþ/þTRAMPþ
mice exhibited PIN histology in their prostate and 75%
demonstrated epithelial-stromal tumor of the SV.
RKIP/TRAMPþ mice at 30 weeks exhibit undiffer-
entiated PCa with no observable luminal epithelial
cells. In RKIP/TRAMPmice, no tumors developed.
Taken together these data suggest that RKIP deficiency,
while insufficient as a solitary event to promote
PCa initiation, decreases latency for prostate tumor
initiation and progression in TRAMP mice.
RKIPDef|ciency Increases Incidence ofMetastasis
To determine if RKIP expression impacts the inci-
dence of metastasis, metastases were scored both by
macroscopic observation during necropsy and by
microscopic analysis of organs. Lymph node metasta-
ses were not identified in any group until 30 weeks of
age (Table II). The number of mice with lymph node
metastases were much higher in RKIP/TRAMPþ
mice compared to RKIPþ/þTRAMPþ mice (84% vs.
8%, respectively). Only RKIP/TRAMPþ mice devel-
oped metastases by 30 weeks (53%) with one RKIP/
TRAMPþ mouse demonstrating organ metastasis at
20 weeks (Table III). RKIP/TRAMPþ mice had
between 0 and 6 metastases per mouse (average of
0.84 metastases per mouse) compared to RKIPþ/þ
TRAMPþ mice which had 0–2 in mice (average of 0.08
per mouse) (Fig. 4a). Although lymph node metastases
far outnumbered individual organ metastases, the
Fig. 1. RKIP expression decreases as prostate cancer progresses
to metastasis inTRAMP mice. a: Endogenous levels of RKIP mRNA
in normal prostate, prostate cancer (PCa) and organ metastasis
(Mets) were quantifiedusing real-time quantitative PCR (qRT-PCR).
b-Actin was used to normalize for sample loading. P< 0.05 versus
Normal. b: Immunohistochemical staining for the indicated target
protein(400magnification).
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Fig. 3. Loss of RKIP promotes prostate tumor growth inTRAMP mice. a: Prostates, including tumor when present, were weighed at
30 weeks of age. P< 0.05 versus either TRAMPþ group; #P< 0.05 versus RKIPþ/þ/Trampþ. b: Prostate tissues were collected at the
indicatedtimes andsubjectedtohistologyusinghematoxylinandeosin staining.
Fig. 2. Validation of creating RKIP/TRAMPþmice.Total RNA and protein was collected from prostates of RKIP/TRAMPþ (RTþ),
RKIP/TRAMP (RT), or RKIPþ/þTRAMPþ (RþTþ) mice and subjected to (a) PCR and (b) immunoblot for RKIP and T-antigen
(TAg). c: Prostate tissue was collected frommice with the indicated genotype and subjected to immunohistochemistry for RKIP and TAg
(400).d:TotalRNAderived fromthe anteriorprostate (AP), dorsolateralprostate (DLP) andventralprostate (VP) lobes andliver andlung
frommicewith theindicatedgenotypewas subjectedtoreal-timequantitativePCRforTAgexpression.
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organ metastases were distributed relatively evenly
among multiple sites in the RKIP/TRAMPþ
mice (Fig. 4b,c). With the exception of enlarged peri-
prostatic lymph nodes and grossly visible liver metas-
tases, the remaining metastases were of a microscopic
nature.
RKIPImpacts TumorGrowth and Proliferation
To determine if RKIP deficiency impacts tumor
growth through altering proliferation and/or apopto-
sis we evaluated tumor tissues for Ki67, a marker of
proliferation and for DNA strand breaks (Apoptag), as
an index of apoptosis. RKIP/TRAMPþ mice exhib-
ited higher proliferation rates than RKIPþ/þTRAMPþ
mice at 10 and 20 weeks; however, by 30 weeks the
two groups had similar proliferation rates (Fig. 5a,b).
There was no difference in the apoptotic rate
between the groups (not shown). RKIP inhibits Raf
kinase-mediated activation of MEK and its down-
stream target ERK. To confirm that loss of RKIP
expression translated to increased ERK activation in
TRAMP mouse prostates, we measured phospho-ERK.
Phospho-ERK was increased in the prostate tumors
of RKIP/TRAMPþ mice compared to those of
RKIPþ/þTRAMPþmice (Fig. 5c).
Decreased RKIPExpressionAlone Is Insuff|cientto
PromoteMetastasis in LNCaP
Prostate Cancer Cells
It has been previously demonstrated that re-
expression of RKIP alone is sufficient to inhibit
metastasis in several cancer types including prostate
cancer cells [12] and breast cancer cells [4]. Further-
more, it has been shown that knockdown of RKIP
promotes invasion in both prostate cancer cells [12]
and breast cancer cells [4] in vitro. However, it is
unknown if decreased RKIP expression alone is suffi-
cient to increase metastasis. The findings of this
current report showing that RKIP knockout promotes
metastasis in TRAMP mice suggests that loss of RKIP
expression alone can promote metastasis. However, it
is challenging to eliminate the observed early induc-
tion of tumor growth as a mechanism that contributes
to the increased metastatic rate in the RKIP/
TRAMPþ mice as opposed to an impact on metastatic
activity itself. Accordingly, to determine if loss of RKIP
is sufficient to promote metastasis, we knocked down
RKIP expression in the low metastatic LNCaP cell line
to determine the impact on metastatic rate. In addition,
we transduced LNCaP cells with both empty vector
and RKIP overexpression vector as controls. RKIP was
efficiently knocked down (80%) in the LNCaP cell
line (Fig. 6a). Modulation of RKIP had no impact on
cell growth rate in vitro (Fig. 6b). However, knock-
down of RKIP increased LNCaP’s invasive ability;
whereas overexpression of RKIP decreased its invasive
ability (Fig. 6c). To evaluate the impact of modulated
RKIP expression on LNCaP cells in vivo, the trans-
duced cells were injected into the dorsolateral prostate
lobes of mice, and after 12 weeks, mice were eutha-
nized at which time prostate tumors were weighed and
the body examined for metastases. There was no
difference in tumor weight among the LNCaP cell with
modulation of RKIP expression (Fig. 6d). Gross metas-
tases were only identified in lungs, as previously
described [12], accordingly we quantified lung metas-
tases. Modulation of RKIP expression had no impact
on number of metastases (Fig. 6e). Taken together,
these data indicate that decreased RKIP expression
alone is insufficient to increased metastasis in LNCaP
prostate cancer cells. To determine if loss of RKIP could
enhance metastatic rate in a cell line with a high
metastatic phenotype, we increased and decreased
RKIP expression in C4-2B cells (Supplemental Fig. S1a),
which are a metastatic variant of LNCaP cells [14],
and injected them orthotopically into mice. At 12 weeks
of tumor growth, mice were euthanized and
examined for lung metastases. Similar to LNCaP cells,
TABLEI. Incidence ofMiceWith PrimaryTumor
(Percent)
Genotype 10 weeks 20 weeks 30 weeks
RKIPþ/þ TRAMPþ 0/10 (0) 0/16 (0) 4/12 (33.3)
RKIP/ TRAMP 0/10 (0) 0/10 (0) 0/14 (0)
RKIP/ TRAMPþ 0/12 (0) 7/12 (58) 17/19 (89.5)
TABLEII. Incidence ofMiceWith LymphNode
Metastasis (Percent)
Genotype 10 weeks 20 weeks 30 weeks
RKIPþ/þ TRAMPþ 0/10 (0) 0/16 (0) 1/12 (8)
RKIP/ TRAMP 0/10 (0) 0/10 (0) 0/14 (0)
RKIP/ TRAMPþ 0/12 (0) 0/12 (0) 16/19 (84)
TABLEIII. Incidence ofMiceWithOrganMetastasis
(Percent)
Genotype 10 weeks 20 weeks 30 weeks
RKIPþ/þ TRAMPþ 0/10 (0) 0/16 (0) 0/12 (0)
RKIP/ TRAMP 0/10 (0) 0/10 (0) 0/14 (0)
RKIP/ TRAMPþ 0/12 (0) 1/12 (8) 10/19 (53)
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modulation of RKIP expression in C4-2B cells had
no impact on cell growth rate in vitro or in vivo
(Supplemental Fig. S1b,c). In contrast to LNCaP cells,
overexpression of RKIP decreased C4-2B’s metastatic
rate; whereas, knockdown or RKIP increased their
metastatic rate (Fig. 6f). These results, in conjunction
with the LNCaP results, indicate that decreased RKIP
expression can enhance metastasis in pro-metastatic
background, but decreased RKIP alone is insufficient to
promote metastasis.
DISCUSSION
RKIP has been shown to have metastasis suppressor
activity in several cancer types. The definition of a
metastasis suppressor is that it inhibits components of
the metastatic cascade without an impact on primary
tumor growth [16,17]. Consistent with this definition,
restoring expression of RKIP was shown to decrease
metastasis, yet have no impact on primary tumor
growth in murine models of PCa [12] and breast
cancer [18]. In spite of the large body of evidence that
RKIP suppresses metastasis, the mechanisms through
which it achieves that are not well-defined. The results
presented in this study are the first to provide direct
evidence that decreased RKIP expression decreases
latency of PCa tumor development and promote
metastasis in an autochthonous model of cancer.
The TRAMP mouse model is a commonly used
mouse model to study PCa in mice [19–21]. The
Fig. 4. Loss of RKIP increases metastasis in the TRAMP mouse. At 30 weeks of age, RKIP/TRAMPþ (RTþ), RKIP/TRAMP
(RT), or RKIPþ/þTRAMPþ (RþTþ) micewere subjected to necropsy. Prostate, brain, lung, liver, kidney, pancreas, testes were examined
grosslyor histologically (at least10 sectionsper tissue) for evidence of tumor.RKIP/TRAMP (RT) didnotdevelop any tumor andis not
depicted in this figure. a: the percent of mice for each genotype delineated by number of metastases is plotted. b: the percent of mice
for each genotype delineated by metastatic site is plotted. c: representative images of prostate and metastases (PIN, prostate
intraepithelialneoplasia).Hematoxylinandeosinstaining.
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prostate lobes of male TRAMP mice undergo a
fairly well-defined progressive development of PCa
mimicking certain aspects of human prostate patholo-
gy beginning with PIN through distant metastasis
with a high penetrance. As with any mouse model of
human disease, there are limitations of the TRAMP
model including the preponderance of neuroendocrine
phenotype of PCa [22] which represents a small
population of PCa patients [23]. We initially set out to
use the TRAMP model to obtain in vivo validation
of the metastasis suppressor function of RKIP in an
autochthonous model of PCa. Our strategy was to
generate RKIP-deficient-TRAMP mice to test the
hypothesis that RKIP deficiency will increase the
incidence of metastasis in TRAMP mice. As hypo-
thesized, RKIP deficiency led to increased metastasis;
however, unexpectedly, we identified that RKIP
knockout also decreased latency for the appearance of
neoplastic prostate changes. These findings appear
to conflict with the earlier observations that loss of
RKIP expression promotes metastasis independent of
an impact on tumor growth suggesting that altered
kinetics of progression results in the apparent increase
in metastasis. It is also possible that the tumors initiate
earlier in the context of RKIP deficiency, but grow at
the same rate as in the RKIP intact state. In this
situation; although growth rates are similar, at any
particular time point the RKIP-deficient tumors will be
larger than the RKIP-intact tumors due to the RKIP-
deficient tumors starting growth at an earlier time
point.
There is a preponderance of evidence in multiple
tumor types that loss of RKIP expression promotes
metastasis, in part, through enhancing invasion
[2,18,24–26]. The mechanisms through which loss of
RKIP promotes invasion include increased activity
of NFkB [4], through modulation of let-7-mediated
chromatin remodeling [18] and increased activity of
STAT3 [2]. These activities have the potential to
increase metastasis independent of an impact on cell
growth as would be expected for loss of metastasis
suppressor activity. The decreased latency on tumor
initiation we observed in the RKIP-deficient state
also provides a mechanism that could contribute to
the increased metastasis observed in these animals
compared to RKIP-intact animals. Specifically, the
development of cells with metastatic capability may be
dependent on epigenetic and genetic events that occur
as the tumor grows [27,28]. The earlier initiation of
tumor growth in the RKIP-deficient state allows for
both (1) more time for pro-metastatic molecular events
to occur and (2) an increasing number of cancer cells
being present (i.e., more target cells). Overall, these
events would result in more opportunities for develop-
ment of cells with metastatic ability, including the
increased invasiveness induced by loss of RKIP.
Tumor growth culminates from a balance between
cell proliferation and apoptosis. Decreased RKIP ex-
pression has been shown to inhibit chemotherapy-
induced apoptosis [9,11,29]. In our study, there was no
impact on endogenous apoptosis in the prostate tissue
or the prostate tumors. Together, these observations
Fig. 5. Loss of RKIP increases prostate cell proliferation and ERKactivation.Prostatewere collected fromRKIP/TRAMPþ (RTþ) and
RKIPþ/þTRAMPþ (RþTþ) and subjected to immunohistochemistry for Ki-67 at the indicated timepoints. a: Onehundredcells in10 random
fieldswere counted to generate the %Ki67 positive cells permouse andresults areplotted. P< 0.05 versus RKIPþ/þTRAMPþ for the same
time point. b: representative Ki67 immunohistochemistry. c: Prostate tumors were collected at 30 weeks from the indicatedgenotypes of
mice.Totalproteinwasharvestedandsubjectedtoimmunoblotforphospho-ERK1/2,ERK1/2,TAg,andRKIP.
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suggest that in the basal state, RKIP has minimal
impact on apoptosis, but when a stressor is intro-
duced, RKIP has pro-apoptotic effects. In contrast to
no impact on endogenous apoptosis, at the 10- and
20-week time points, there was an increase in the
number of proliferative cells found in the non-tumor
prostate tissue of the RKIP deficient compared to RKIP
intact TRAMP mice. However, this difference was lost
by 30 weeks when both groups had tumor present in
the prostates. The increased proliferative state of
the non-tumor prostate in the RKIP deficient mice
could contribute to shorter latency for tumor initiation
in these mice. It is unclear why the proliferative
rate decreases as the tumors develop; however, this
is consistent with a previous report in which the
proliferative state of prostate epithelial cells was
increased and associated with activation of p38MAPK,
JNK, and Erk1.2 during prostate tumor initiation,
but was decreased, as was the activation of the
signaling molecules, with emergence of poorly differ-
entiated metastatic prostate cancer [30]. As RKIP
impacts multiple signaling pathways, it is possible
that the overall balance of their activity in the RKIP
deficient state results in differential impact on non-
tumor versus tumor prostate epithelial cells as in the
previous report. Along these lines, it is possible that
in the RKIP negative background, effects on immune
modulatory signaling pathways that RKIP affects,
such as NFkB and Stat3, could alter the immune
response to tumors allowing for altered tumor prolifer-
ation and progression.
Although several studies in a variety of cancer types
have shown that overexpression of RKIP in cell lines
inhibits metastasis of their xenografts in vivo [8,31],
it has not been previously demonstrated that loss of
RKIP expression increases metastasis in an in vivo
Fig. 6. Decreased RKIP expression is insufficient to increasemetastatic rate of LNCaP prostate cancer cells. a: LNCaP cells were trans-
ducedwithempty vector (pBP)orconstructs to overexpressFLAG-RKIP (fRKIP)orknockdownRKIP (shRKIP) andselectedwithpuromycin
to create stable cell lines.Totalproteinwas collectedand subjected to immunoblot forRKIPor FLAG.Bandsweremeasuredusingdensitome-
try. b: Cells were plated equally and counted for a plating efficiency on day1and counted on days 3, 8, and10 after plating. c: LNCaP cells
were plated in a modified Boyden chamber assay. Invasive ability was defined as proportion of cells invading through the coatedmembranes
dividedbynumberofcellsmigrating throughuncoatedmembranes. P< versuspBP.d,e:LNCaPcells (105 cells)with theindicatedmodulation
of RKIP were injected into dorsolateral lobe of prostates of SCID mice (n¼10/group) and allowed to form tumors for 12 weeks at which
timemicewere euthanized. d:Prostate tumorswereremovedandweighed. e:Lungswere excised, andeach lungwas sectioned four times at
300mm intervals. Sections were stainedwith prostate specific antigen to identifymetastases.Metastases were counted in all four sections
of one sample and averaged.Data are reported as the averagemetastases per sample for10mice. f: C4-2B cells (105 cells) with the indicated
modulation of RKIP (i.e., empty vector (pBP), overexpression (fRKIP) or knockdown (shRKIP))were injected into dorsolateral lobe of pros-
tates ofSCIDmice (n¼10/group) andallowedto formtumors for12weeks atwhich timemicewere euthanized; lungs excisedandmetastases
quantified as descried in ‘‘(e)’’.Data are reported as the averagemetastases per sample for10 mice. P< 0.05 versus pBP; #P< 0.05 versus
fRKIP.
300 Escara-Wilke et al.
The Prostate
model. Our finding that decreased RKIP expression in
the TRAMP background increased the metastatic rate
suggests that loss of RKIP contributes to metastasis
in vivo. However, it does not demonstrate that loss
of RKIP alone is sufficient as TRAMP mice readily
develop metastasis and thus other changes, in addition
to loss of RKIP, may be required for metastasis to occur.
Our finding that knockdown of RKIP alone in the
LNCaP cells did not enhance their metastatic rate taken
together with the observation of increased metastasis
in the RKIP deficient TRAMP mice suggests that loss
of RKIP alone is insufficient to induce metastasis;
however, in the appropriate pro-metastatic context it
contributes to the development of metastasis. Further-
more, that restoring RKIP expression in several different
cancer types inhibits metastasis, suggests that loss of
RKIP is required for metastasis to occur.
CONCLUSIONS
In summary, we identified that loss of RKIP
enhanced the development of metastasis in an autoch-
thonous model of prostate cancer. However, loss of
RKIP alone was not sufficient to promote metastasis in
a cell line with a low metastatic rate. In light of the
previous reports that restoring RKIP expression inhib-
its metastasis the current findings indicate that the loss
of RKIP is necessary but not sufficient to promote
prostate cancer metastasis. This finding further sup-
ports the important role that RKIP plays in metastasis
and provides an additional rationale to explore
methods to target RKIP for therapy of prostate cancer
to prevent metastasis. Additionally, identification
of signaling pathways that cooperate with loss of
RKIP to promote metastasis may provide additional
therapeutic targets.
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